Table 10 Clinical trials of other drug conjugates for lung cancer treatment
From: Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Drug name | Target | NCT number | Status | Study phase | Number of subjects | Primary endpoint | Study start date |
|---|---|---|---|---|---|---|---|
PEN-866 | Hsp90 | NCT03221400 | Recruiting | I/II | 340 | DLTs | Aug 2017 |
EC1456 | FR | NCT01999738 | Completed (NA) | I | 93 | Not provided | Oct 2013 |
MBC-11 | Ca +  | NCT02673060 | Completed (NA) | I | 18 | AEs | Nov 2015 |
CBP-1008 | TRPV6 | NCT04740398 | Recruiting | I | 143 | AEs | Mar 2019 |
Vintafolide | EGFR | NCT02049281 | Terminated | I | 3 | Cmax | May 2014 |
Vintafolide | EGFR | NCT01688791 | Terminated | I | 37 | DLTs | Sep 2014 |
Vintafolide | EGFR | NCT01002924 | Completed (NA) | II | 1 | AEs | Dec 2009 |
Vintafolide | EGFR | NCT00511485 | Completed (NA) | II | 43 | Clinical benefit | Jul 2009 |
Vintafolide | EGFR | NCT00308269 | Completed (NA) | I | 32 | MTD | Aug 2007 |
Vintafolide | EGFR | NCT01577654 | Completed (NA) | II | 203 | PFS | Dec 2013 |
BMS-753493 | – | NCT00546247 | Terminated | I/II | 26 | MTD | Mar 2010 |
BMS-753493 | – | NCT00550017 | Terminated | I/II | 39 | MTD | Dec 2007 |
EC0489 | FR | NCT00852189 | Completed (NA) | I | 65 | MTD | Dec 2011 |
EC0225 | – | NCT00441870 | Completed (NA) | I | 77 | MTD | Feb 2007 |
ACE1702 | HER2 | NCT04319757 | Recruiting | I | 36 | AEs | May 2020 |
SBT6050 | HER2 | NCT04460456 | Not recruiting | I | 58 | DLTs | Jul 2020 |
SBT6050 | HER2 | NCT05091528 | Terminated | I/II | 2 | DLTs | Feb 2022 |
SBT6290 | Nectin4 | NCT05234606 | Withdrawn | I/II | 0 | DLTs | Mar 2022 |
BDC-1001 | Toll | NCT04278144 | Recruiting | I/II | 390 | AEs | Feb 2020 |
XMT-2056 | STING | NCT05514717 | Suspended | I | 171 | DLTs | Jan 2021 |
ADCT-301 | Treg cells | NCT03621982 | Terminated | I | 78 | AEs | Nov 2018 |
ORM-5029 | HER2 | NCT05511844 | Recruiting | I | 87 | MTD | Oct 2022 |